Astellas Pharma obtained the FDA's approval to market Astagraf XL, an extended-release version of the firm's Prograf, or tacrolimus, for prevention of kidney transplant rejection. The approval makes Astagraf XL the first once-daily tacrolimus formulation available to kidney transplant patients in the U.S. The approval was based on data from two late-stage trials involving 1,093 patients.

Related Summaries